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Abstract 
In Vitro Maturation (IVM) of human oocytes is an innovation in Assisted Reproductive Technology (ART). It is 
believed more patient-friendly than conventional In Vitro Fertilization (IVF) method. It is a simple protocol that needs 
only less injection of ovarian stimulation for the patients and fewer blood sample and ultrasound scans, so this 
technique may become more favorable. Patients are also prevented from higher cost treatments and quite long control 
in the hospital. However, there are some problems to be addressed, such as how to improve the success rate, how to 
assure the safety and to avoid the health risk for the offsprings. Modification in IVM medium and optimizing the IVM 
protocols have increased the results in some studies. However, further investigation related to all aspects influencing 
the human oocyte maturation in vitro is still needed to make it enable to be a routine practice in ART centers for a 
defined group. 
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Abstrak 
Maturasi oosit in vitro atau In Vitro Maturation (IVM) terhadap oosit manusia merupakan suatu inovasi dalam 
Teknologi Reproduksi Berbantu (TRB). Teknik ini dianggap lebih nyaman bagi pasien dibandingkan dengan metode 
Fertilisasi In Vitro (FIV) konvensional.  Metode IVM ini sederhana dan hanya membutuhkan lebih sedikit penyuntikan 
obat stimulasi ovarium ke pasien serta lebih sedikit pemeriksaan darah dan ultrasonografi, sehingga memungkinkan 
untuk menjadi suatu pilihan yang disukai oleh pasien. Pasien juga bisa terhindar dari biaya terapi yang lebih mahal 
serta waktu kontrol yang lama di rumah sakit. Namun demikian, terdapat beberapa masalah yang perlu ditangani 
terkait metode ini, seperti bagaimana meningkatkan angka keberhasilan serta memastikan keamanan dan mencegah 
resiko kesehatan pada anak yang akan dilahirkan. Modifikasi pada medium IVM serta pengoptimalan protokol IVM 
telah meningkatkan hasil pada beberapa penelitian. Penelitian yang lebih mendalam terkait semua aspek yang 
mempengaruhi maturasi in vitro oosit manusia masih diperlukan menuju penerapan rutin prosedur IVM untuk 
kelompok pasien tertentu di pusat-pusat pelayanan TRB. 
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INTRODUCTION 
In vitro maturation (IVM) of oocytes is an 
emerging technique that allows immature oocytes 
retrieved from females to reach their maturation in the 
artificial medium outside of the natural condition. It can 
be applied either in natural or stimulated ovarian cycle. 
For human application, however, unstimulated ovarian 
cycle becomes an interesting choice, especially for 
women with high risk of ovarian hyperstimulation 
syndrome (OHSS). In fact, this method was initially 
applied in human as alternative procedure to get 
mature oocyte without risk of OHSS in patients with 
polycystic ovarian syndrome (PCOS). However, 
through its development, IVM for human oocytes can 
be used for several purposes.
1,2
 
Although it provides some promising benefits, 
but over the past decade, the achievement of this 
Tinjauan Pustaka 
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technique is still suboptimal. The absence of risk for 
OHSS, cost efficiency and comfortable method for 
patients have been considered as the positive points 
of IVM. In contrast, it is still not applied regularly in 
assisted reproductive treatment (ART). Its success 
rate in human reproduction is also still limited. IVM 
oocytes are believed still prematurely developed. 
Furthermore, it seems that people have not fully 
understood about all aspects that may influence the 
outcomes. In addition, how to optimize the success 
rate is still remains unclear.
1,3,4
 
It still becomes a critical challenge to reveal the 
factors contributing the competence of in vitro oocyte 
maturation and how to control the process. It is 
believed that the success of IVM is related to the 
combined nuclear and cytoplasmic maturation of the 
oocytes. Several approaches have been taken to gain 
more understanding about the mechanism, including 
the studies on the composition of maturation medium 
and how to improve the IVM protocols. However, 
previous studies still have not succeeded to explain 
clearly the process and detailed contributors toin vitro 
maturation oocyte.
1,2,4
 
 
EARLY DEVELOPMENT AND PROMISING 
POTENTIAL OF IVM FOR HUMAN 
IVM came as an improvement to classic 
methods of in vitro fertilization (IVF) for a certain group 
of patients. It is basically an innovation to grow 
immature oocytes to reach the stage of metaphase 
II.During its development, IVM for human oocytes 
seems to be a promising alternative to conventional 
IVF procedures because of several 
advantages.Therefore, talking about IVM cannot be 
separated from the history of IVF development.
1,2
 
Pincus and Enzman in 1935 were the first 
scientists who proved the capability of immature rabbit 
oocyte, as the model of mammalian oocytes, to gain 
its maturation after removing from the follicle. For 
human oocytes, Edwards and colleagues were the 
pioneers in the experiments of IVM. In 1965, they were 
success to mature human oocytes in a culture 
medium, and in 1968, they reported the 
accomplishment of in vitro fertilization (IVF) for in vitro 
matured human oocyte.
1,4,5
 
Since IVF technique was developed in mid-
nineteenth century, a lot of innovation and 
improvement have been gained regarding the 
applicability of this method on animals as well as 
human reproductive. At first, IVF in human was 
performed without an initial ovarian stimulating 
treatment and only used a single oocyte retrieved from 
the natural cycle. Along with its development, 
stimulated cycles were elaborated to yield more 
oocytes.
2
 
Ovarian stimulation which is usually used to 
produce more mature oocytes, seems not entirely 
safe. It is also clearly associated with a high risk of 
OHSS in females involving treated with IVF. Although 
the range of its reported incidence is between 0.5%-
14%, but some patients with OHSS may end up with a 
severe condition, and even fatal, especially if they 
have PCO and PCOS. It is believe that the best way to 
avoid OHSS is by avoiding the ovarian superovulation. 
Therefore, the best option to yield more number of 
human oocytes safely has become an issue since 
several decades ago.
6,7
 
In vitro maturation (IVM) of oocytes presents 
another way to produce more mature oocytes without 
depending on a set of ovarian stimulating procedures. 
In IVM, preliminary ovarian stimulations are not really 
needed, although some doctors still perform a short 
stimulation. It provides a better hope, especially for 
women with PCO and PCOS, to lower or even abolish 
the risk of OHSS. In this method, immature oocytes 
are collected from the follicles, and then their 
maturation is reached in an artificial medium that is 
modified to mimic the natural condition in the ovary. 
Even though this strategy now can be used for several 
reasons in clinical aspects, but this strategy was 
initially aimed for the patients with PCO with a risk of 
OHSS. IVM is also considered as a patient-friendly 
method. Patients are not required to have a routine 
injection for a certain time, as administering in 
stimulated cycles. They also do not need to be closely 
controlled in the clinics or hospitals, as applied in 
ovarian stimulating protocols, to avoid OHSS. 
Therefore, the cost the patients should pay 
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may also be lowered.
8-11 
IVM technique nowadays is also combined with 
the ovarian cryopreservation for the patients suffering 
from any cancers that may interfere their reproductive 
organs. Oocytes can be cryopreserved from any 
stages of development and from any ages except 
post-menopausal, therefore, female cancer patients 
have more chance to maintain their fertility for even 
after chemotherapy or radiotherapy is performed. IVM 
is suggested as one method to harvest the mature 
oocytes later on, and then IVF can be carried out to 
assist the reproduction. Therefore, it is also considered 
as the best choice for these patients to preserve their 
fertility in long term purpose.
8,10
 
 
CHALLENGES OF IVM APPLICATION FOR 
HUMAN OOCYTES 
IVM of human oocytes still meets some 
challenges. Its application is still limited and has not 
been a routine practice in ART yet, although it has 
been being developed for about 40 years. Although 
various studies have been conducted in many centers 
to find out the most suitable approach in IVM 
application on human oocytes, but it seems that the 
results on human oocytes are still poor. From study by 
Trounson et al in 1994, only twenty percent of all 
unovulatory PCOS patients involved in that project 
presented a healthy pregnancy and born an alive baby 
from the fertilized IVM oocyte. Besides, the safety 
issue of the offspring’s health still becomes a concern 
and debatable matter.These things may lower the 
intention to put IVM as the regular choice for infertile 
patients. Basically, how to improve the success rate 
and to assure there are no health-related risks on the 
children conceived through IVM procedure are the 
main challenges in IVM practice for human 
nowadays.
2,9,12-14
 
The quality of IVM medium is important for the 
accomplishment of IVM in human. It seems still difficult 
to endure the intrafollicular maturation program for the 
next couple days in vitro, resulting in a poor rate of live 
offspring produced for human. To provide a suitable 
artificial medium for human oocyte maturation in vitro 
is still under continuous studies until now. The best 
medium composition is still unclear. Also, it is still 
difficult to create the similar condition in vitro with the 
real ovarian follicular environment. However, as for 
any other species undergoing IVM, the appropriate 
condition of this synthetic medium is really needed for 
human oocyte maturation, and also to support the 
oocyte potential for fertilization and further embryo 
development.
11,13-15 
 
The certainty that all processes of oocyte 
growth have been achieved is also important for the 
success of IVM. Oocyte maturation is considered as 
the climax of a long process in oocyte growth from 
female germ cells. Oocyte maturation should reach 
both nuclear and cytoplasmic maturation. Nuclear 
maturation is defined as the ability of oocytes to 
continue meiosis and develop from prophase I to 
metaphase II. Following resumption of meiosis, 
germinal vesicles breakdown and nuclear membrane 
dissolves. Separated homologous chromosomes then 
is extruded into periviteline space, becoming first polar 
body. After that, through second meiosis, oocytes 
reach the stage of metaphase II. Meanwhile, 
cytoplasmic maturation is characterized by some ultra-
structural and biochemical changes in oocyte 
cytoplasm that are necessary for fertilization and 
further embryo development. It is believed that there is 
a significant increase in oocyte cytoplasmic organelles 
and structures during its maturation process, such as 
cortical granules. All of these things should 
occursychronizedly during oocytes maturation. And 
any aberrations or deficiencies within those processes 
may result in either fertilization block or implantation 
failure.
16-19
 
Even though nuclear maturation may happens 
spontaneously when inhibitor signal in follicles is 
suppressed, it does not guarantee that cytoplasmic 
maturation will present correctly. Studies on mice 
oocytes suggested that most problems with oocyte 
maturation are associated with cytoplasmic 
reprogramming rather than aberrations in meiosis. 
Furthermore, its effect is rarely detectable during the 
early stage of oocyte development, but more 
frequently manifested in the stages of late cell-division 
and peril-implantation. Therefore, follow-up of post-
fertilization development should be a valid indicator for 
oocyte developmental competence.
17-19 
 
Obviously, cytoplasmic maturation combined 
simultaneously with nuclear maturation is also required 
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for successful oocyte maturation in vitro. The less 
competence in cytoplasmic maturation of IVM oocyte 
compared to in vivo matured oocyte is highlighted as 
the cause of low blastocyst rates of IVM oocytes 
although they present the good nuclear maturation. 
Some studies showed results that there are no 
significant differences regarding nuclear maturation 
between in vivo and in vitro matured oocytes. The 
oocytes derived from both ways of maturation show 
almost the same rates of fertilization and cleavage. 
However, clinically embryonic developmental was 
poor; with only 18% of pregnancy rate and 40% of 
them had early miscarriage.
4,12,14,15 
Regarding the safety issue, there are only few 
studies about IVM safety on human related to the 
health status of the children born following IVM. In 
general, current data shows an increase of health 
problems in children conceived through ART. They are 
related to chromosomal anomalies, major congenital 
malformation, and imprinting disorders. But is not clear 
whether it is really due to the method of ART used or 
the underlying diseases of the parents that cause 
infertility problems.
2
 According to a study by Buckett et 
al in 2007, there is no significant difference regarding 
baby’s congenital abnormality between normal 
conception and ART. In addition, the cases are lower 
for IVM than for ICSI, although ICSI is used in all IVM. 
The explanation for this condition can be due to 
abnormal sperm that may be used in ICSI, not fully 
due to the method itself. Other studies by Shu-Chi et al 
in 2006 and Soderstom-Antitla et al in 2006 also 
suggested that chromosomal constitution and mental 
development were not significantly different between 
IVM and spontaneously conceived children.
2,12,14,15
 
It seems that the safety and health-problem 
risks of IVM really depends on the ability of the 
oocytes to gain nuclear and cytoplasmic properly in 
vitro, and also the selection of sperm used in ICSI for 
IVM oocyte. If the IVM and IVF procedure are done 
correctly, no worries on health and safety issue are 
needed. Available data currently likely to reassure that 
IVM is quite safe and no need to worry regarding issue 
of congenital malformations, physical or neurological 
developmental delay.
2
 
 
 
CHANCES FOR IMPROVEMENT 
Some studies on IVM for human oocytes have 
identified several strategies to improve the success 
rate, and the possibility to have it as a routine practice 
for a defined group of patients. Some are related to 
IVM media modification and patient selection criteria, 
while other studies are based on oocyte quality and 
endometrium preparation. Including here are FSH 
priming, follicles selection and hormone therapy for 
endometrium.
3,7,10
 However, not all of these have been 
fully understood and gained general agreement. Some 
are still debatable and require further research.       
Although not many studies based on human 
regarding IVM media, but some suggested the benefit 
of gonadotrophin and protein supplementations. 
Adding FSH and LH into IVM and culture media is 
believed to increase the oocyte maturation and 
embryo cleavage in vitro. Meanwhile, another study 
showed the significant increase in maturation, 
implantation and clinical pregnancy rates when 
immature human oocytes were matured in IVM 
medium with 10% (v/v) maternal serum addition 
compared to 2% (w/v) human serum albumin (HSA). 
Nevertheless, further studies are still needed regarding 
the best concentration of the media compositions.
7,9,11
 
The patient’s characteristic may influence the 
result of IVM, therefore a careful selection of the 
patients for IVM is a necessity. It has been well known 
that young-aged women undergoing IVM, as any other 
ARTs, may have a better result than the older ones. 
Age of 35 is assumed to be the borderline. Some 
believe that regularity of the women’s cycle may also 
affect the outcome. Although at the earlier time of IVM 
application on human it was indicated for irregular 
cycle and anovulatory women with PCOS, but 
Mikkelsen et al in 1999 pointed out that normo-
ovulatory young women showed better endpoint. On 
the other hand, others suggested that young women 
with PCO and PCOS are the best choice for IVM, 
because they have more antral follicles available. 
However, generally it is agreed that young women 
attempting IVM may have a better outcome.
15,16,20
 
Regarding FSH priming, some studies agreed 
that pretreatment with FSH during the early follicular 
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phase is useful to improve the result of IVM by having 
more oocytes retrieved, while others disagreed. In 
1998, Wynn et al stated that FSH priming can promote 
the number of mature oocyte in vitro. Besides, study 
by Mikkelsen and Lindenberg in 2001 have showed 
the improved pregnancy and implantation rate in 
women with PCOS after FSH priming 150 IU per day 
for 3 days and retrieving oocyte 2-3 days later when 
follicles reached 10 mm in size, whereas there was no 
improvement found when this method was applied to 
women with regular cycles. Similar to this result, the 
study by Junk and Yeap in 2012 also found the benefit 
of FSH priming in term of improving oocyte viability 
and subsequent development of embryo in PCOS 
patients.
2,3,7,16
 
Another thing that may improve the success of 
IVM is timing for immature oocyte retrieval. A study by 
Junk and Yeap in 2012 suggested the ideal time is 
when follicle size has been 10-12 mm. It is related to 
the oocyte competence that may impact the embryo 
developmental potential. But, it is still a matter of 
debate. Some others claimed it is better to retrieve 
oocytes from smaller size follicle due to the possibility 
of the non-dominat follicles, especially in unstimulated 
cycle, to experience early atresia.
3,6,7
 
Beside those things above, endometrial 
preparation is also suggested to improve IVM success 
rate for human application. It is important to have 
uterus ready for implantation and subsequent 
pregnancy. In general practice, estradiol is used since 
the day of oocyte retrieval. The dosage is determined 
by endometrial thickness, ranging between 6-10 mg 
per day. Progesterone is also given as 200 mg every 8 
hours, started on the day of fertilization until 12 weeks 
of pregnancy.
6
 
A study by fertility specialists in Western 
Australia in 2012 claimed that a better success rate of 
IVM for human oocyte can be achieved by optimizing 
the IVM protocol as they proposed. Based on their 
prospective cohort study on women with PCO and 
PCOS seeking for infertility treatment in their hospital, 
they found the increased implantation, clinical 
pregnancy and live-birth rates. They did FSH priming 
to the patients (100 IU or 150 IU) for 3 days and 
selected follicles for aspiration whose size is 10 to 12 
cm. Unlike the most current protocol of hormonal 
therapy for endometrial preparation, estrogen was 
given earlier, initialed 2 days before oocyte retrieval. 
And finally, they performed blastocyst-stage single-
embryo transfer. However, the study showed that 
oocyte maturation and fertilization rates were similar to 
the previous studies in human clinical infertility 
treatment.
3,20
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